GE Healthcare presented results from an interim phase II study of its developmental fluciclatide radiopharmaceutical at this week's SNM annual meeting in Salt Lake City.
Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging, according to the Chalfont St. Giles, U.K.-based vendor. The study, presented in collaboration with the U.S. National Cancer Institute (NCI), is part of a larger multisite clinical program being conducted in the U.S., Europe, India, and Korea. GE hopes the program will detect and measure patients with various solid tumor types, including melanoma and renal cell carcinoma.
In the study presented at SNM, NCI associate investigator Esther Mena, MD, shared preliminary data on the uptake and retention properties of fluciclatide in solid tumors. The research found that the biodistribution of fluciclatide permitted visual analysis of the target lesion on PET/CT as a means to demonstrate variable solid tumor uptake and retention, sometimes with heterogeneous distribution within the tumor, GE said.
Related Reading
Mediwatch to sell GE ultrasound scanners, June 8, 2010
FDA approves GE optical imaging agent, June 2, 2010
GE debuts SenoBright mammography upgrade, June 1, 2010
GE touts Visipaque study results, May 27, 2010
GE launches CT scanner in Europe, May 25, 2010
Copyright © 2010 AuntMinnie.com
